"Designing Growth Strategies is in our DNA"
Ataxia is characterized as a degenerative disease of the nervous system. People suffering from ataxia generally experience dysarthria, abnormalities while walking or uncoordinated use of their arms or hands. There are different types of ataxia such as Friedreich’s ataxia, Ataxia –telangiectasia, spinocerebellar ataxias, and episodic ataxia. According to the National Institute of Neurological Disorders (NINDS), Friedreich ataxia is considered as the most common type of hereditary ataxia that usually affects at least 1 in 50,000 populations globally every year.
Currently, there are no specific treatments or cure available for the treatment of ataxia. Generally, various therapies such as speech & language therapy, occupation therapy, and physiotherapy and medications are used to treat the symptoms associated with ataxia. Episodic ataxia is controlled using acetazolamide. Antibiotics or antiviral medications are sometimes used to treat acquired ataxia and sometimes vitamin E supplements are used to treat ataxia for patients with vitamin E deficiency.
Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for ataxia. For instance; MIN-102, which is being studied by Minoryx Therapeutics, S.L., is currently in phase-2 clinical trials for the study of Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients
To know how our report can help streamline your business, Speak to Analyst
At present around 72% of the pipeline candidates for Ataxia are in the phase-1 and phase-2 stage. More than half of the studies are sponsored by government research organizations and many are sponsored by industries.
The report on ‘Ataxia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Ataxia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Ataxia.
The report on ‘Ataxia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.